Alnylam Pharmaceuticals, Inc. - Common Stock — Quarterly Financial Statistics (NASDAQ:ALNY) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -118.31 M153.73 M325.11 M163.56 M70.5 M 712.9 M Cash from investing activities 113.77 M-141.38 M501.11 M-37.17 M25.54 M 348.1 M Cash from financing activities 44.08 M53.76 M-448.35 M45.32 M15.71 M -333.56 M Free cash flow -118.31 M153.73 M325.11 M163.56 M48.67 M 691.07 M

News

Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 — The Stock Now Trades Above $1,200

Strength in Chipmakers Boosts Stock Indexes

Alnylam: Unexpected Rival Trial Failure Improves Core TTR Franchise Outlook (ALNY)

Stocks Climb on Strength in Chipmakers

AstraZeneca's Stock Drops on Wainua's Setback in ATTR-CM Study

Why AstraZeneca Crashed 8%, Leading Three Rivals, Including Pfizer, To Jump

Stock Market Today: S&P 500 Gains Traction Amid Iran News; Arm, Dell Lead Upside (Live Coverage)

Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth?

Alnylam Pharmaceuticals, Inc. (ALNY) Discusses ALN-6400 RNAi Therapy Targeting Plasminogen for Rare Bleeding Disorders Transcript

Alnylam Pharmaceuticals, Inc. (ALNY) Discusses ALN-6400 RNAi Therapy Targeting Plasminogen for Rare Bleeding Disorders - Slideshow (NASDAQ:ALNY) 2026-06-25

Regeneron's Applications for gMG Drug Accepted by FDA and EMA

Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?